Phase I Study of [<sup>68</sup>Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)Odrade Gondry, Marleen Keyaerts, Catarina Xavier et al.|Journal of Nuclear Medicine|2023Cited by 45
Phase II Trial Assessing the Repeatability and Tumor Uptake of [<sup>68</sup>Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast CarcinomaOdrade Gondry, Marleen Keyaerts, Vicky Caveliers et al.|Journal of Nuclear Medicine|2024Cited by 40
The Prognostic Value of CD206 in Solid Malignancies: A Systematic Review and Meta-AnalysisJens Debacker, Wouter Huvenne, Odrade Gondry et al.|Cancers|2021Cited by 40
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Bart Neyns, Yanina Jansen et al.|Cancers|2021Cited by 36
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumabGil Awada, Bart Neyns, İsa Aykut Özdemir et al.|Annals of Oncology|2018Cited by 4